VIRAL GENOTYPE IS A NON MODIFIABLE FACTOR THAT IMPACTS THE PROGRESSION OF LESIONS 1
1 in 4 HPV 16+ patients with low grade lesions will progress to CIN 2 immediately 1
1 in 3 HPV 16+ patients with low grade lesions will progress to CIN 2 in 5 years 1
Papilocare® rst treatment with clinical superiority in lesion regression at 6 months in HR-HPV+ patients 2,3
OBSERVATIONAL STUDY
CLINICAL TRIAL
NCT 04002154
NCT 04002154
Regression of cervical lesions ◊ at 3, 6 and 12 months 2,3
200
100 90 80 70 60 50 40 30 20 10 0
*
**
150
88%
179
80%
100
52%
56%
50
59
14*
0
VISIT 1 (BASELINE)
VISIT 2 (6 MONTHS)
GLOBAL (12 MONTHS)
3 months n=69 p=0.0168
n=66 p=0.0034
6 months
1.Demarco M, Egemen D, Raine-Bennett TR, et al. A study of partial human papillomavirus genotyping in support of the 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis 2020;24:144–7. 2. Serrano, Luis et al. “E cacy of a Coriolus versicolor-Based Vaginal Gel in Women With Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study.” Journal of lower genital tract disease vol. 25,2 (2021): 130-136. doi:10.1097/LGT.0000000000000596 3.Cortés Bordoy, Javier et al. “E ect of a Multi-Ingredient Coriolus-versicolor-Based Vaginal Gel in Women with HPV-Dependent Cervical Lesions: The Papilobs Real-Life Prospective Study.” Cancers vol. 15,15 3863. 29 Jul. 2023, doi:10.3390/cancers15153863
Made with FlippingBook - Online magazine maker